Title
The elementome of calcium-based urinary stones and its role in urolithiasis

Permalink
https://escholarship.org/uc/item/2824c6rc

Authors
Ramaswamy, K
Killilea, DW
Kapahi, P
et al.

Publication Date
2015-09-01

DOI
10.1038/nrurol.2015.208

Peer reviewed
The elementome of calcium-based urinary stones and its role in urolithiasis

Krishna Ramaswamy, David W. Killilea, Pankaj Kapahi, Arnold J. Kahn, Thomas Chi and Marshall L. Stoller

Abstract | Urolithiasis affects around 10% of the US population with an increasing rate of prevalence, recurrence and penetrance. The causes for the formation of most urinary calculi remain poorly understood, but obtaining the chemical composition of these stones might help identify key aspects of this process and new targets for treatment. The majority of urinary stones are composed of calcium that is complexed in a crystalline matrix with organic and inorganic components. Surprisingly, mitigation of urolithiasis risk by altering calcium homeostasis has not been very effective. Thus, studies to identify other therapeutic stone-specific targets, using proteomics, metabolomics and microscopy techniques, have been conducted, revealing a high level of complexity. The data suggest that numerous metals other than calcium and many nonmetals are present within calculi at measurable levels and several have distinct distribution patterns. Manipulation of the levels of some of these elemental components of calcium-based stones has resulted in clinically beneficial changes in stone chemistry and rate of stone formation. The elementome—the full spectrum of elemental content—of calcium-based urinary calculi is emerging as a new concept in stone research that continues to provide important insights for improved understanding and prevention of urinary stone disease.

Introduction

Urinary stone disease is a considerable burden on public health worldwide. In the USA, urolithiasis is estimated to occur in 8–15% of the population, resulting in an annual cost of approximately 4 billion dollars to the US national healthcare system. In developing countries, urinary stone disease affects up to 25% of the population and can result in death when adequate urological care is lacking. Stone recurrence rates are approximately 10% at 1 year, 33% at 5 years and 50% at 10 years. The disease also increasingly occurs in previously less affected populations, including children and black and Hispanic individuals. Furthermore, the prevalence of urinary calculi is increasing in the USA and many other countries in parallel with the rising rates of obesity and metabolic syndrome. Yet, after decades of research, little progress has been made in defining the aetiology of urolithiasis or designing strategies for the prevention of urinary stones in susceptible patients. Analysis of the chemical components within calcium-based urinary stones is one approach that is being used by researchers to gain insights into the disease process.

Compositional analysis of urinary calculi is not a new strategy; component analysis of stones has been suggested to have begun as far back as the end of the 18th century. Currently, we appreciate that urinary stones can be classified based on several specific chemical components, including oxalate, phosphate, apatite, struvite, uric acid, cystine and a few other rare categories. Mixtures of these chemical compositions in a single stone are also common, resulting in a spectrum of different stone chemistries. However, 80–90% of calculi are calcium-based concretions, in which the calcium component is usually complexed to organic or inorganic matrices in specific crystalline formations.

Although many of the uncommon stone types have defined aetiologies, the calcium-based stones are mostly idiopathic in nature. Undoubtedly, the urinary concentrations of Ca2+ and its binding partners, such as oxalate, are important, but this measure alone is not sufficient to enable prediction of who will ultimately form stones, or how frequently. Thus, a large amount of research has been performed to discover which other components within the calculus could be measured and possibly altered to reduce stone formation. Several studies of calcium-based stones found matrix proteins, organic acids, polysaccharides and a variety of metals other than calcium within the calculi, revealing a more complex composition than originally expected.

Of the stone components, the metal constituents are arguably the most well studied; overall however, only few studies investigating the effects of various metals on stone formation and physical properties have been reported. Understanding the full range of elements that can be components of calcium-based urinary stones—the elementome—is a key goal of our group. In addition to the important knowledge basis formed by previous studies, several important publications in...
The majority of human urinary stones are primarily composed of crystalline calcium salts but many other metals and nonmetals are detectable with concentrations ranging over 10 orders of magnitude. The contribution of elements other than calcium to the formation, recurrence or physical properties of human urinary stones is generally poorly defined. Over the past 50 years, 20–30 studies of elemental stone content have been published and their findings can be summarized to produce a working elementome of the human calcium-based urinary stone. The amount of some elements within human calcium-based urinary stones does not correlate with their normal urinary concentrations, suggesting that accumulation or other processes affect the elemental composition of stones. Further refinement of the elementome of calcium-based urinary stones is warranted because it is likely to reveal novel opportunities for monitoring lithogenesis and new targets for therapeutic intervention.

In addition, a few reported values for some elements (for example, chromium and cobalt) seem unrealistically high, suggesting metal contamination of the samples or typographical errors in the report. Other, low-mass elements such as carbon and nitrogen are likely to be present in the stones as well, particularly in the protein matrix, but cannot be easily measured using conventional elemental analysis techniques. These issues will be better resolved when additional studies become available that use next-generation technologies and cover a wider range of elements and larger sample sets with more discrete mineral types than the current studies.

The proposed composition of the elementome of calcium-based stones (Figure 1) also raises several questions that should be the basis of future studies. For example, previous investigations demonstrated that many metals other than calcium are present in these stones but the reasons for this diversity are unclear. Many metals that occur in calculi in small amounts could simply reflect urinary clearance of these metals but mechanisms that specifically concentrate these metals within a stone could also exist. In addition, the implications of the new knowledge of the elementome of urinary calculi for urolithiasis therapy need to be addressed. Metals other than calcium could affect stone formation rates or the physical properties of stones. Therapeutic alterations in the urinary levels of some of these metals could possibly change the chemical content of developing stones and alter the amenability of the stones to treatment.

This Review summarizes our current knowledge of the elementome of calcium-based urinary calculi. First, we provide a brief overview of the history of research and techniques used in elemental analysis of stones. We then discuss the findings of studies investigating those elements that are found in calcium-based stones and note when data published for those elements have not been extensively investigated. Throughout, we highlight results that have clinical relevance and could be important in shaping the future therapeutic strategies in urinary stone disease.

### Measuring the elementome

Compositional analysis of urinary stones began in the 18th century, but the available methods would have been limited to chemical reactivity tests after laborious separation procedures. Furthermore, only the most abundant elements within the stone would have been detectable with these approaches. In the 1950s, a number of optical techniques for elemental analysis were developed and soon adopted by biomedical researchers, including atomic absorption spectroscopy, atomic emission spectroscopy and fluorescence spectroscopy. Further technical developments made mass spectrometric atomic spectroscopy and X-ray fluorescence techniques available for routine elemental analysis. These techniques have unique operational advantages but they are also accompanied by challenges that can affect the quality of elemental analysis.
All of these methods have been used to study urinary stones and have resulted in a refined understanding of the elemental composition to part-per-trillion levels. Furthermore, improvements in proteomics, metabolomics and next-generation microscopy techniques have revealed that the elemental content of the stone is highly complex and heterogeneously distributed.25–27 These insights have generated new hypotheses regarding the key effectors of stone formation and recurrence, resulting in studies in which urinary stone disease was attenuated through alteration of the homeostasis of some of these effectors.

### The elementome of urinary stones

For many elements, little detail regarding their normal urinary levels and effects in urological and renal physiology and pathology is known (Table 2);28 in the field of stone research, only a limited number of studies have assessed elemental content of urinary calculi, and of calcium-based stones in particular. Other elements, apart from the ones reported to date, might be present apart from the ones reported to date, might be present.

<table>
<thead>
<tr>
<th>Study [PMID]</th>
<th>Stone type(s)†</th>
<th>Stones analysed (n)</th>
<th>Elements analysed (n)</th>
<th>Identity of evaluated elements</th>
<th>Analysis method(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ohta et al. (1957)177 (no PMID)</td>
<td>A, B, C, D, E, F, M</td>
<td>8</td>
<td>10</td>
<td>Ca, Cu, Fe, K, Mg, Mn, Na, Pb, Zn</td>
<td>Colorimetric and FP</td>
</tr>
<tr>
<td>Nagy et al. (1963)29 [13937198]</td>
<td>A, M</td>
<td>85</td>
<td>21</td>
<td>Ag, Al, Bi, Ca, Cd, Cr, Cu, Fe, K, Mg, Mn, Mo, Na, Ni, P, Pb, Si, Sn, Sr, Zn</td>
<td>LA-OES</td>
</tr>
<tr>
<td>Meyer et al. (1977)18 [844995]</td>
<td>A, M</td>
<td>10</td>
<td>40</td>
<td>Ag, Al, Au, As, B, Ba, Be, Bi, Cd, Ce, Co, Cr, Cu, Fe, Ga, Ge, Hg, In, K, Li, Mg, Mn, Mo, Na, Ni, P, Pb, Pt, Pb, Sb, Sr, Sn, Sr, Ti, U, V, W, Zn, Zr</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Levinson et al. (1978)178 [627468]</td>
<td>A, B, C, D, F, M</td>
<td>186</td>
<td>20</td>
<td>Ag, Al, Be, Cd, Co, Cr, Cu, Fe, K, Mg, Mn, Mo, Na, Ni, Pb, Si, Sr, Ti, V, Zn</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Wandt et al. (1984)179 [6486462]</td>
<td>A, F, M</td>
<td>37</td>
<td>3</td>
<td>Ca, Mg, P</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Durak et al. (1988)180 [3191333]</td>
<td>A, C, F, M</td>
<td>29</td>
<td>5</td>
<td>Cd, Cu, Fe, Mg, Pb</td>
<td>AAS</td>
</tr>
<tr>
<td>Wandt et al. (1988)181 [3401656]</td>
<td>A, D, F, M</td>
<td>102</td>
<td>13</td>
<td>Al, Ca, Cu, Fe, K, Mg, Mo, Na, Pb, S, Sr, Zn</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Durak et al. (1990)182 [2351193]</td>
<td>A, C, F, M</td>
<td>47</td>
<td>5</td>
<td>Cd, Cu, Fe, Mg, Zn</td>
<td>AAS</td>
</tr>
<tr>
<td>Komleh et al. (1990)183</td>
<td>M</td>
<td>60</td>
<td>6</td>
<td>Ca, Cu, Mg, Mn, P, Zn</td>
<td>Colorimetric and AAS</td>
</tr>
<tr>
<td>Hofbauer et al. (1991)185 [1984106]</td>
<td>A, D, M</td>
<td>25</td>
<td>14</td>
<td>Al, Cd, Co, Cr, Cu, Fe, Li, Mn, Mo, Ni, Pb, Sr, Ti, Zn</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Durak et al. (1992)186 [1376483]</td>
<td>A, B, C, D, M</td>
<td>37</td>
<td>4</td>
<td>Ca, Cu, Fe, Zn</td>
<td>AAS</td>
</tr>
<tr>
<td>Höbath et al. (1993)187 [8212413]</td>
<td>A, B, C</td>
<td>10</td>
<td>10</td>
<td>Ce, Eu, Ga, La, Lu, Nd, Sm, Tb, Tb, Yb</td>
<td>NAA</td>
</tr>
<tr>
<td>Küpeli et al. (1993)188 [8508898]</td>
<td>A</td>
<td>20</td>
<td>4</td>
<td>Cu, Fe, Mg, Zn</td>
<td>AAS</td>
</tr>
<tr>
<td>Perk et al. (2002)189 [12053034]</td>
<td>A, B, C, D, M</td>
<td>45</td>
<td>5</td>
<td>Al, Ca, Cd, Ni, Pb</td>
<td>AAS</td>
</tr>
<tr>
<td>Fang et al. (2005)190 [16193228]</td>
<td>A, B, C, D, F</td>
<td>7</td>
<td>6</td>
<td>Ca, K, Mg, Na, Pb, Sm</td>
<td>LIBS</td>
</tr>
<tr>
<td>Atakan et al. (2007)191 [17203355]</td>
<td>A</td>
<td>104</td>
<td>4</td>
<td>Cu, Fe, Mg, Zn</td>
<td>AAS</td>
</tr>
<tr>
<td>Bazin et al. (2007)192 [17492279]</td>
<td>A, B, C, D, F, M</td>
<td>78</td>
<td>7</td>
<td>Cu, Fe, Pb, Pb, Se, Sr, Zn</td>
<td>XRF</td>
</tr>
<tr>
<td>Abboud et al. (2008)193 [17476757]</td>
<td>A, B, F, M</td>
<td>110</td>
<td>16</td>
<td>Al, Ca, Co, Cr, Cu, Fe, K, Mg, Mn, Mo, Na, Ni, P, S, Sr, Zn</td>
<td>AAS</td>
</tr>
<tr>
<td>Turgut et al. (2008)194 [18176803]</td>
<td>A</td>
<td>38</td>
<td>7</td>
<td>Cr, Cu, Fe, Mg, Mn, Pb, Zn</td>
<td>AAS</td>
</tr>
<tr>
<td>Słojewski et al. (2010)195 [20024629]</td>
<td>A, B, C, D</td>
<td>219</td>
<td>29</td>
<td>Al, As, B, Ba, Ca, Cd, Cr, Cu, Fe, Ge, Hg, I, K, Li, Mg, Mn, Mo, Na, Ni, Pb, S, Se, Sr, Sn, Sr, V, Zn</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Bazin et al. (2011)196 [21997917]</td>
<td>M</td>
<td>3</td>
<td>1</td>
<td>Sr</td>
<td>XANES</td>
</tr>
<tr>
<td>Blaschko et al. (2013)197 [23260568]</td>
<td>A, B, D, M</td>
<td>4</td>
<td>5</td>
<td>Ca, Fe, Pb, Sr, Zn</td>
<td>XRF</td>
</tr>
<tr>
<td>Giannossi et al. (2013)198 [23141501]</td>
<td>A, B, C, D, F, M</td>
<td>48</td>
<td>9</td>
<td>Ca, Cr, Cu, Fe, K, Mg, Mn, Pb, Zn</td>
<td>AAS and ICP-OES</td>
</tr>
<tr>
<td>Abdel-Gawad et al. (2014)199 [25155408]</td>
<td>A, B, C, D, E, F</td>
<td>74</td>
<td>21</td>
<td>Al, As, B, Ba, Ca, Cd, Co, Cr, Cu, Fe, K, Mg, Mo, Mn, Na, Ni, P, S, Se, Sr, Zn</td>
<td>ICP-OES</td>
</tr>
<tr>
<td>Bazin et al. (2014)200 [24365928]</td>
<td>M</td>
<td>6</td>
<td>1</td>
<td>Sr</td>
<td>XANES</td>
</tr>
<tr>
<td>Keshavarzi et al. (2015)201 [25433503]</td>
<td>A, B, D, F, M</td>
<td>39</td>
<td>23</td>
<td>Al, Ba, Ca, Cd, Co, Cr, Cu, Fe, K, Mg, Mn, Mo, Na, Ni, P, Pb, Rb, S, Se, Sr, V, Zn</td>
<td>ICP-MS</td>
</tr>
</tbody>
</table>

*Elemental studies including evaluation of calcium-based urinary stones are listed, excluding unpublished thesis data or articles that could not be easily evaluated owing to their age or other factors. †Urinary stone types are identified as A, calcium oxalate; B, calcium phosphate or brushite; C, magnesium phosphate or struvite; D, uric acid; E, xanthine; F, cystine; M, mixed stone type. Abbreviations: AAS, atomic absorption spectroscopy; FP, flame photometry; ICP-MS, inductively coupled plasma mass spectrometry; ICP-OES, inductively coupled plasma optical emission spectroscopy; LA-OES, laser-ablation optical emission spectroscopy; LIBS, laser-induced breakdown spectroscopy; NAA, neutron activation analysis; PMID, PubMed unique identifier; XANES, X-ray absorption near edge structure; XRF, X-ray fluorescence.
phosphorus and chloride constitute the bulk of most urinary stones. In this Review, we focus on the data that are available for the stone components that generally make up <1% of the stone mass, which we discuss following their order of abundance in the proposed stone elementome (Table 1).

Sulphur
Sulphur is an essential nonmetal nutrient that is obtained either from sulphur-containing amino acids or from sulphate in the diet. Sulphur is required to make cysteine, methionine, glutathione and many other sulphur-containing compounds within the body. The effects of elemental sulphur on calcium-based stones are mostly unknown. However, convincing evidence exists that the increased sulphate load in kidneys of individuals with high animal protein consumption is associated with an increased risk of stone formation. This effect is primarily driven by elevated uric acid and reduced citrate levels in the urine, which are both known risk factors that promote formation of calcium-based stones. In addition, urinary sulphate excretion has been shown to be higher in patients who have urinary stones than in individuals who do not form stones, although this effect might be related to increased levels of urinary Ca\(^{2+}\) in stone formers: sulphate can bind Ca\(^{2+}\), competing with sites in a growing stone that can bind Ca\(^{2+}\), which keeps the Ca\(^{2+}\) ions in solution and increases the amounts of both Ca\(^{2+}\) and sulphate that are excreted in the urine. For this reason, other investigators have argued that therapeutically increasing urinary sulphate concentrations could actually reduce the risk of calcium-based stones.

Sulphur-containing compounds have been found in calcium-based stones, but the exact identities and amounts of such molecules have not been well established. Free sulphate is not known to directly bind to crystalline formations found in calcium-based stones; however, small amounts of proteins are found within these stones, so any cysteine or methionine residues would account for the sulphur content. In addition, other sulphur-compounds that are present in urine at low levels, including thioesters and mercaptans, could react with components within a stone. Although reduction of protein consumption has been shown to reduce the risk of stone formation, no direct proof exists that this risk reduction specifically relates to decreased levels of sulphur-containing amino acids or other sulphur-containing compounds. On the one hand, metabolism of sulphur-containing amino acids increases the acid levels in the urine but, on the other hand, sulphate and other sulphur-compounds might act as inhibitors of stone formation by competing for free urinary Ca\(^{2+}\) with the Ca\(^{2+}\) binding sites of a stone, inhibiting crystallization. To our knowledge, no studies have been reported that prospectively altered sulphur homeostasis to determine whether such a change has an effect on calcium-based lithogenic risk.
### Table 2 | Summary of urinary content and regulation of the elements identified within human kidney stones*

<table>
<thead>
<tr>
<th>Element</th>
<th>Proportion renally excreted</th>
<th>Hormonal regulation</th>
<th>Normal urinary levels range [mg/dl]$^a$</th>
<th>Normal urinary amounts range [mg daily]</th>
<th>Urinary stone levels range (median) [mg/g]</th>
<th>Lithogenic potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ca</td>
<td>Major</td>
<td>Yes</td>
<td>NR</td>
<td>100–300</td>
<td>34.5–383 (217)</td>
<td>Prolithogenic</td>
</tr>
<tr>
<td>P</td>
<td>Major</td>
<td>Unknown</td>
<td>2.30–4.10</td>
<td>NR</td>
<td>6.10–23.5 (13.3)</td>
<td>Prolithogenic</td>
</tr>
<tr>
<td>Cl</td>
<td>Major</td>
<td>Yes</td>
<td>NR</td>
<td>3,890–8,850</td>
<td>11.5</td>
<td>Prolithogenic</td>
</tr>
<tr>
<td>S</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>1.40–26.0 (8.60)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Mg</td>
<td>Major</td>
<td>Yes</td>
<td>NR</td>
<td>72.9–122</td>
<td>0.0576–35.0 (4.38)</td>
<td>Antilithogenic</td>
</tr>
<tr>
<td>Na</td>
<td>Major</td>
<td>Yes</td>
<td>920–6,600</td>
<td>0.402–15.0 (2.50)</td>
<td>Prolithogenic</td>
<td></td>
</tr>
<tr>
<td>K</td>
<td>Major</td>
<td>Yes</td>
<td>975–4,880</td>
<td>0.245–5.60 (1.30)</td>
<td>Antilithogenic</td>
<td></td>
</tr>
<tr>
<td>Zn</td>
<td>Minor</td>
<td>Unknown</td>
<td>0.018–0.085</td>
<td>0.15–1.20</td>
<td>0.0157–0.891 (0.200)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Al</td>
<td>Major</td>
<td>Unknown</td>
<td>3×10⁻³–0.001</td>
<td>NR</td>
<td>0.00718–2.10 (0.00266)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Sr</td>
<td>Unknown</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>0.0145–5.60 (0.130)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Fe</td>
<td>Minor</td>
<td>Unknown</td>
<td>2×10⁻⁴–0.007</td>
<td>0.003–0.098</td>
<td>0.00530–5.60 (0.102)</td>
<td>Unknown</td>
</tr>
<tr>
<td>B</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>0.00847–0.272 (0.100)</td>
<td>Antilithogenic</td>
</tr>
<tr>
<td>Pb</td>
<td>Major</td>
<td>Unknown</td>
<td>0.008</td>
<td>NR</td>
<td>4.64×10⁻⁵–0.720 (0.0329)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Cu</td>
<td>Minor</td>
<td>Unknown</td>
<td>2×10⁻⁴–0.008</td>
<td>0.003–0.035</td>
<td>0.00220–7.49 (0.0245)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ni</td>
<td>Major</td>
<td>Unknown</td>
<td>1×10⁻⁴–0.01</td>
<td>NR</td>
<td>0.00205–0.100 (0.0144)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Si</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>0.00846</td>
<td>Unknown</td>
</tr>
<tr>
<td>Li</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>1.28×10⁻⁴–0.0166 (0.00834)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ti</td>
<td>Minor</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>0.00760</td>
<td>Unknown</td>
</tr>
<tr>
<td>Cr</td>
<td>Major</td>
<td>Unknown</td>
<td>1×10⁻⁵–2×10⁻⁴</td>
<td>NR</td>
<td>4.55×10⁻⁵–0.450 (0.00690)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Rb</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>1.0–3.0</td>
<td>0.00250–0.007 (0.00475)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Sb</td>
<td>Major</td>
<td>Unknown</td>
<td>0.001</td>
<td>NR</td>
<td>0.0043</td>
<td>Unknown</td>
</tr>
<tr>
<td>Mn</td>
<td>Minor</td>
<td>Unknown</td>
<td>5×10⁻⁵–9.8×10⁻⁴</td>
<td>NR</td>
<td>2.31×10⁻⁵–1.10 (0.0043)</td>
<td>Unknown</td>
</tr>
<tr>
<td>V</td>
<td>Major</td>
<td>Unknown</td>
<td>8×10⁻⁶–2.4×10⁻⁵</td>
<td>NR</td>
<td>2.38×10⁻⁶–0.0082 (0.00422)</td>
<td>Unknown</td>
</tr>
<tr>
<td>I</td>
<td>Major</td>
<td>Unknown</td>
<td>0.011–0.0129</td>
<td>NR</td>
<td>0.00414</td>
<td>Unknown</td>
</tr>
<tr>
<td>Co</td>
<td>Major</td>
<td>Unknown</td>
<td>1×10⁻⁵–2×10⁻⁴</td>
<td>NR</td>
<td>2.16×10⁻⁵–0.500 (0.00302)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Se</td>
<td>Major</td>
<td>Unknown</td>
<td>7×10⁻⁶–0.016</td>
<td>NR</td>
<td>0.001–0.0362 (0.00266)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ba</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>NR</td>
<td>0.00174–0.00873 (0.00180)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Mo</td>
<td>Major</td>
<td>Unknown</td>
<td>8×10⁻⁵–0.0034</td>
<td>NR</td>
<td>2.03×10⁻⁵–8.00×10⁻² (1.74×10⁻²)</td>
<td>Unknown</td>
</tr>
<tr>
<td>As</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>0.005–0.05</td>
<td>1.59×10⁻⁵–0.0202 (0.00148)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Cd</td>
<td>Major</td>
<td>Unknown</td>
<td>5×10⁻⁵–4.7×10⁻⁴</td>
<td>NR</td>
<td>2.81×10⁻¹–2.68×10⁻³ (8.02×10⁻³)</td>
<td>Prolithogenic</td>
</tr>
<tr>
<td>Sn</td>
<td>Major</td>
<td>Unknown</td>
<td>0.004</td>
<td>NR</td>
<td>1.56×10⁻⁴</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ce</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>1.24×10⁻⁴</td>
<td>1.04×10⁻⁴</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ge</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>9.5×10⁻⁵</td>
<td>7.3×10⁻⁵</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nd</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>5.9×10⁻⁵</td>
<td>4.6×10⁻⁵</td>
<td>Unknown</td>
</tr>
<tr>
<td>Gd</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>2.95×10⁻⁵</td>
<td>2.4×10⁻⁵</td>
<td>Unknown</td>
</tr>
<tr>
<td>La</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>1×10⁻⁵</td>
<td>3×10⁻⁵</td>
<td>Unknown</td>
</tr>
<tr>
<td>Tb</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>2×10⁻⁵</td>
<td>2×10⁻⁵</td>
<td>Unknown</td>
</tr>
<tr>
<td>Lu</td>
<td>Major</td>
<td>Unknown</td>
<td>NR</td>
<td>2×10⁻⁵</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

*Elements are listed in rank order of weight-normalized elemental content within calcium-based stones (Figure 1). The clinical reference range values are listed depending on whether they are usually measured as urinary concentration or daily urinary content. For some metals only a single value, which should not be exceeded under normal circumstances, is listed. Abbreviation: NR, not reported.

---

© 2015 Macmillan Publishers Limited. All rights reserved
Magnesium
Magnesium is an essential metal micronutrient required as a cofactor in a range of metabolic, bioenergetic, regulatory and cell signalling functions. Magnesium also has structural roles during biomineralization, with 50–60% of the total amount of magnesium in the body found in bone.39 The effects of magnesium status on urinary stone disease have been the subject of several investigations. Studies have shown decreased calcium oxalate crystallization and growth in the presence of high concentrations of Mg2+, 39–41 and others have demonstrated increased lithogenesis when urinary Mg2+ levels are low.62 Magnesium has an important role as a nephrolithiasis inhibitor, acting more effectively in combination with citrate—magnesium citrate complexes slow the nucleation and growth rate of stones.41 Mg2+ also competes with Ca2+ for binding to oxalate in the urine, therefore, reducing the number of calcium oxalate crystals.60 Moreover, severe restriction of dietary magnesium has been reported to cause nephrocalcinosis and stone formation in rats.43 By contrast, other studies have shown that urinary magnesium excretion was not significantly different between patients with stones and healthy controls,39,44,45 yet another group found urinary Mg2+ levels to be higher in healthy controls compared with patients with stones.46

Although not conclusive, the current evidence suggests that urinary magnesium can generally be antilithogenic within the renal system. Thus, urinary magnesium concentration is regularly measured in 24-h urine analysis, and the Mg2+:Ca2+ ratio in the urine is sometimes used as an estimate of stone risk, with a higher ratio being more antilithogenic.57

The effects of magnesium within urinary calculi have been investigated in a few studies. A study using molecular dynamics computer simulations showed that the presence of Mg2+ reduces the average size of the calcium oxalate and calcium phosphate aggregates; for calcium oxalate aggregates, Mg2+ destabilized the ionic pairing of Ca2+ and oxalate.68 Moreover, authors of another report found that calcium oxalate monohydrate stones that contained lower levels of magnesium (around 3.3 g/kg) were more resistant to fragmentation in shockwave therapy than stones containing higher levels of magnesium (around 6.1 g/kg).49

Despite the encouraging results in experimental studies, the usefulness of manipulating magnesium homeostasis as a treatment strategy for urinary stone disease is unclear, as clinical studies have generated conflicting results.41,50,51 One review published in 2005 concluded that the available evidence does not justify the use of magnesium salts alone as a therapy for calcium oxalate urinary stones for most patients, but that the addition of magnesium supplementation to conventional therapeutic modalities is useful, especially in patients who are at risk of magnesium deficiency.52 Importantly, although the kidneys are the primary determinant of magnesium homeostasis, the gastrointestinal tract also has a major role through its ability to regulate the absorption of Mg2+ from the diet. Thus, the effectiveness of magnesium supplementation might be complicated by changes in alimentary absorption. In addition, no sensitive measure of adequacy exists to monitor changes in dietary magnesium intake or overall magnesium balance, making it difficult to assess magnesium status in a patient. Given the demonstrated benefits of magnesium in multiple aspects of stone disease, further investigation of the usefulness of magnesium supplementation in well controlled studies is highly warranted.

Sodium
Sodium is an essential metal micronutrient and Na+ acts as the principle cation of extracellular fluid, with key functions in control of osmotic balance, body fluid volume regulation, ionic gradients and signal transduction. Na+ also has a structural role, as it interacts with and neutralizes many anionic chemical molecules, proteins and membrane structures.53 Elevated urinary sodium levels result in increased calcium excretion and high urinary calcium excretion is known to be one of the main risk factors for developing calcium-based urinary stones.54,55 Curhan et al.56 reported a strong epidemiological connection linking high Na+ intake and nephrolithiasis in the Nurses’ Health Study I of 91,731 women, showing a clear increasing trend in the risk of developing stones as the quintiles of salt intake rise (relative risk 1.30 for sodium intake >4 g/day). Others have shown similar results.57,58 Elevated urinary Na+ excretion can also lead to hypocitraturia, resulting in the reduction in levels of the natural stone inhibitor citrate and a concomitant increase in calcium-based urinary stone risk.59,60

Interventional studies investigating the role of dietary sodium restriction have mostly demonstrated favourable results. Dietary salt reduction resulted in decreased urinary Ca2+ excretion.51,62 Borghi et al.57 prospectively followed male idiopathic calcium oxalate stone formers for 5 years who were instructed to maintain a diet that was low in salt and animal protein and found that the diet lowered urinary calcium levels and was associated with a 50% reduction of calcium oxalate stone recurrence rates. Taylor et al.64 demonstrated a lower recurrence of all urinary stone types in individuals consuming a healthier diet (lower amounts of salt and dairy fat, but higher intake of fruits, vegetables and whole grains) compared with individuals consuming a less healthy diet. Nouvenne et al.64 reported that a reduction in salt intake of 8 g/day returned elevated urinary calcium levels to normal levels in a cohort of hypertensive patients followed for 3 months. Dietary sodium reduction seems to be an effective way to reduce calcium-based urinary stone recurrence rates.

By contrast, our group found that dietary sodium supplementation resulted in an increased voided urine volume and decreased the relative risk supersaturation ratio for calcium oxalate stones in patients with a history of hypocitraturic calcium oxalate nephrolithiasis.65 Urinary excretion of calcium, oxalate and uric acid were not changed, suggesting that sodium restriction is inappropriate in patients with hypocitraturia and recurrent urinary stones. Sodium supplementation might be beneficial in these patients because it can promote fluid
Within bone hydroxyapatite, 2+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The usefulness of manipulating zinc homeostasis to affect stone formation remains unclear. To our knowledge, no studies have been reported that prospectively alter zinc homeostasis to determine whether such manipulation has an effect on lithogenic risk. However, using a Drosophila melanogaster model of stone formation, our group has found that increased dietary zinc intake increased the rate of stone formation, whereas addition of the zinc-selective chelator N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine to the food decreased the rate.44 In addition, manipulating zinc levels in stones might change the physical properties of the stones. Researchers found that low concentrations of zinc, along with magnesium and manganese, made calcium oxalate monohydrate stones more resistant to fragmentation in shockwave therapy compared with stones containing higher levels of zinc.49 Interest in the role of zinc in urinary stone disease seems to be growing based on the increasing number of studies that focus on this metal in the context of urolithiasis.

Aluminium
Aluminium is a metal that is not considered essential, as no metabolic role specific for this element has ever been described. Rather, aluminium is regarded as a toxic metal, which is abundant in the environment and might cause disease when intake levels are elevated; however, this claim is controversial.45 One study found an association of the aluminium levels in stones with the aluminium levels in hair and urine of the same patient, suggesting that stone aluminium content reflects environmental exposures.46 In an in vitro study, researchers found that physiological concentrations of Al3+ affected calcium phosphate crystal growth; however, its inhibitory activity towards calcium phosphate crystal growth in urine seemed to be insufficient to support a regulatory role in stone growth.14 To our knowledge, no studies investigating whether aluminium content of a stone is correlated to its physical properties have been published. Equally, no studies have been published that prospectively altered aluminium homeostasis to determine whether such modification has an effect on lithogenic risk.

Strontium
Strontium is a metal that is considered nonessential, as no specific metabolic role has been described for it. However, this element is sometimes considered beneficial because it can strengthen the hydroxyapatite crystal structure in bone.57,58 Similar to zinc, strontium is found in many types of biomineralization processes in the body, including bone, teeth and urinary stones, and is thought to generally substitute for calcium.99–101 Within bone hydroxyapatite, strontium preferentially replaces calcium at the Ca2+ crystal position.102 Strontium ranelate is used clinically to increase bone volume and trabecular thickness,103 although one study suggests that the actual effect of strontium on crystal structure in hydroxyapatite is highly variable depending on dose.98 In vitro experiments using nanobacteria revealed strontium incorporation in early stone formation,104 but few other studies on strontium incorporation into human urinary stones exist. In a Drosophila larval model, researchers discovered that strontium could accumulate into urinary stone concretions to a much greater degree than calcium, when supplemental Sr2+ was added to the diet.105 However, the exact role of strontium in calcium-based lithogenesis is still unclear.

Whether the presence of elevated strontium has an effect on the physical properties of urinary calculi is also unclear, but it is known that strontium strengthens hydroxyapatite,106 so some calcium-based stones might be similarly affected. Data from a study by our group suggest that strontium co-localizes with calcium in calcium-based stones, in which it is present primarily as strontium apatite.107 This finding suggests that strontium hydroxyapatite, similar to calcium hydroxyapatite, might be a nidus in calcium-based lithogenesis. We are aware of no published studies in which strontium homeostasis was prospectively altered to determine a possible effect on lithogenic risk. As strontium ranelate has been clinically used for several years to increase bone mineral density and decrease fractures,108 determining whether lithogenesis rates change in patients on strontium ranelate therapy would be interesting.

Iron
Iron is an essential metal micronutrient required as a cofactor for numerous proteins in which it can have catalytic, regulatory and ligand-binding roles;109 however, the effect of iron on the lithogenic process is undefined. Iron can bind oxalates and phosphates, which might interfere with calcium-based crystallization.109,110,111 However, iron can also form complexes with citrate, a natural inhibitor of stone formation, rendering the citrate unavailable for binding with calcium and, thus, might promote stone formation.112 Although one earlier study failed to detect iron in calcium oxalate stones,18 several newer reports have found considerable concentrations of iron in calcium oxalate and calcium phosphate stones.110,111,112 Investigators in one report noted that decreased urinary excretion of iron correlated with low shockwave lithotripsy success rates in patients with calcium oxalate stones.112 No studies that prospectively altered iron homeostasis to determine effects on lithogenic risk currently exist.

Boron
Boron is considered to be a metalloid that is nonessential, as no specific metabolic role for this element in animals has ever been described. By contrast, boron is essential for plants. However, boron has been proposed as a micronutrient in humans, owing to developmental defects in boron-deficient animals, as well as associations between decreased risk of certain cancers and increased dietary boron intake.113

No studies have been reported that evaluate boron status and lithogenic risk. Boron might promote bone development and could possibly be used as a therapeutic agent for osteoarthritis and osteoporosis.114
The mechanism by which boron improves bone health is not fully understood but it might affect magnesium and phosphorus homeostasis or cellular membrane integrity. Boron is present within calcium-based urinary stones, but little understanding of the physiological relevance of boron content exists; also, no direct association between the physical properties of stones and boron levels in urine or a stone has been reported. However, some studies on boron supplementation and risk of urinary stones have been published. One report found that supplemental boron resulted in decreased urinary calcium and oxalate levels in postmenopausal women, but only when magnesium intake was low. In preliminary studies, a small number of patients treated with boron had decreased urinary calcium levels without serious adverse effects. However, more evidence is needed to be able to fully evaluate the clinical utility of boron supplementation. Given the increasing popularity of boron supplements for bone health, investigation of the effect of boron on lithogenesis would be worthwhile.

**Lead**

Lead is a nonessential, toxic metal that causes disease when intake levels are elevated. No studies have been reported that evaluate lead status and lithogenic risk. Lead has biophysical characteristics similar to calcium, so the finding that lead can accumulate in bone is not surprising. Lead has also been detected in urinary stones and correlations of lead content with other metals and stone chemistry have been studied. One study found an association of the lead levels in stones with the lead levels in hair and urine of the same patient, suggesting that stone lead content reflects environmental exposures. No additional studies have been reported that evaluate lead content within calcium-based stones.

**Copper**

Copper is an essential metal micronutrient required as a cofactor for numerous proteins in which it can have catalytic and regulatory roles. Copper homeostasis affects bone biomineralization, as severe copper deficiency results in osteoporosis. Four studies from one group demonstrated that copper salts inhibited the crystallization of calcium oxalate \textit{in vitro} and in rat models. By contrast, another report suggested that copper could inhibit certain types of crystal aggregation (particularly calcium phosphate crystal formation) but not calcium oxalate crystallization. Similarly, one study found that copper excretion was decreased in patients who form calcium-based stones compared with controls, but other investigators have reported increased copper excretion in patients prone to developing calcium-based stones. Currently, the effects of copper on lithogenesis and on the physical properties of stones are unclear. In one study, variation of copper concentrations in the organizational matrix of calcium oxalate stones affected stone hardness; hence, the authors proposed that low concentrations of copper in calcium oxalate stones might confer resistance to shock wave lithotripsy.

**Nickel**

Nickel is a metal that is not considered essential, but a role as a potential micronutrient has been proposed, owing to the effects of nickel on glucose metabolism and amino acid synthesis in animal models. Nickel has not been studied extensively with regards to lithogenesis. One study demonstrated significantly lower urinary and serum nickel levels for active calcium stone formers compared with healthy individuals, but overall the effects of nickel on stone formation remain unclear. No studies of how nickel content of stones might be correlated with their physical properties or whether altering nickel homeostasis affects lithogenic risk have been published.

**Silicon**

Silicon is considered to be a nonessential metalloid, but it has been proposed to be a micronutrient, owing to observations of adverse changes in bone formation, collagen deposition, and acid phosphatase activity under experimental silicon deficiency in animal models. Most of the silicon in the body is present in bone and connective tissue and, therefore, can be incorporated into biomineralized formations. However, we are not aware of any published studies evaluating the relationship between silicon balance and lithogenic risk. Furthermore, the effect of silicon content on stone properties in calcium-based stones has not been studied. Silicon has been proposed to help regulate calcium and magnesium homeostasis, but mechanistic details are lacking. Of note, chronic use of antacid trisilicates can lead to increased urinary stone formation, and these stones are rich in silicon and have less calcium content than commonly found in calcium-based stones. No evidence exists that altering silicon homeostasis affects lithogenic risk.

**Lithium**

Lithium is a metal that is not considered to be an essential nutrient and it has not been studied in detail with regards to lithogenesis. Lithium is a potent inhibitor of the Na\(^+\)/dicarboxylate cotransporters 1 and 3 that reabsorb citrate from the urine; Zhang et al. have proposed that lithium might be useful as a therapeutic to increase urinary citrate, an endogenous inhibitor of calcium-based stone formation. However, elevated lithium levels can be toxic, so the benefits of lithium use to treat urinary stone disease might not outweigh the risks.

**Chromium**

Chromium (as Cr\(^{3+}\)) is an essential metal micronutrient required as a cofactor for glucose tolerance and insulin regulation, whereas other forms of chromium (as Cr\(^{6+}\)) are toxic. No studies that evaluate the influence of chromium status on lithogenic risk have been reported. Chromium is known to accumulate in several tissues including biomineralized tissue, such as bone. Chromium has also been detected in urinary stones and correlations of stone chromium content with the amount of other metals, including calcium and vanadium, in hair
and urine have been reported.96 We are not aware of any studies that have reported a specific role for chromium in the stone formation processes or in the physical properties of calcium-based stones.

**Rubidium**

Rubidium is a metal that is not considered essential for metabolism, although it has been proposed to be a micronutrient, as it has unique neurophysiological activity.134 The effects of rubidium on lithogenesis of calcium-based stones are mostly unknown. Similar to potassium, the rubidium content in stones has historically been considered an epiphenomenon, resulting from interaction with and entrapment in the crystalline matrix of a calculus.110 Possible effects of rubidium content of a stone on its physical properties have not been studied to date and no studies in which rubidium homeostasis has been prospectively altered to determine an effect on lithogenic risk have been published.

**Manganese**

Manganese is an essential metal micronutrient required as a cofactor for key steps in carbohydrate and cholesterol metabolism, amino acid synthesis, bioenergetics and oxidant defence.139 Manganese has an important role in bone mineralization: changes in manganese homeostasis can affect this process, as this element is a cofactor needed in proteoglycan synthesis, which is required for bone matrix formation.140 A study in rats demonstrated that elevated manganese intake increased stone formation rate, as rats receiving high doses of manganese had viscous, gritty urine in the urinary bladder and developed urinary stones.141 Multiple clinical studies have shown that blood and urinary manganese levels in patients with calcium-based stones were lower than in controls.130,131,142 The effects of manganese on the physical properties of stones are unclear. Results of one study suggested that low manganese levels in urinary stones might alter their fragility by making them more susceptible to shockwave therapy.99 Further investigation of the role of this metal in lithogenesis is warranted.

**Vanadium**

Vanadium is a metal that is not essential for metabolism, yet has been proposed to be a micronutrient as it has insulinogenic and neurophysiological activity.143 The effects of vanadium on the lithogenesis of calcium-based stones are mostly unknown; however, this metal is known to accumulate in bone, so incorporation into mineralized tissues might be possible. Whether vanadium content of a stone influences its physical properties is not known.

**Cobalt**

Cobalt is an essential trace element, as a key constituent of vitamin B12, however free cobalt can cause toxicity after occupational or environmental exposure.144 The effect of cobalt on stone formation remains unclear. Słojewski and colleagues96 noted cobalt to be one of five elements, along with vanadium, aluminium, lead and molybdenum, whose content positively correlated with each other in calcium phosphate stones and hair. These findings might reflect environmental exposure to common industrial heavy metals, but the actual reasons for these metal correlations remain unclear. No studies have been published in which cobalt homeostasis was prospectively manipulated to determine whether an effect on lithogenic risk exists.

**Selenium**

Selenium, which has been classified as a nonmetal or a metalloid, is an essential micronutrient in humans. The role of selenium in lithogenesis is not quite clear and is under investigation. One study in rats treated with ethyleneglycol showed that selenium administration inhibited calcium oxalate stone formation; the authors suggested that selenium is incorporated on the crystal surface and inhibits aggregation or induction of new crystals.145 Another group showed that selenium plus vitamin E also protected from hyperoxaluria-induced renal damage in lithogenic rats.146 In canine renal tubular cells, selenium inhibited the development of calcium oxalate monohydrate crystals.147 Although selenium supplementation in experimental models has proved therapeutic, the effects of selenium on calcium-based stone formation in humans have not been reported.

**Molybdenum**

Molybdenum is an essential metal micronutrient and cofactor required for enzymes involved in catabolism of sulphur-containing amino acids and heterocyclic metabolites, such as purines.148 No studies have been published that specifically evaluate molybdenum status and lithogenic risk. Excess dietary molybdenum has been associated with increased urinary uric acid levels, which can promote urinary stone formation, but other studies failed to show the same effect.149,150 Hence, the effects of molybdenum on lithogenesis remain unclear.

**Arsenic**

Arsenic is a metalloid that is not considered essential and is generally regarded as toxic. This element is known to be concentrated in specific geographical locations, which can cause disease when intake levels are elevated.151 Some studies have found higher concentrations of arsenic in urinary calculi made of calcium apatite compared with other calcium-based stones, postulating that arsenic replaces phosphorus in the apatite, owing to its similar charge and size.111 Another study found that dietary arsenic deprivation increased kidney calcium concentrations in female rats fed a standard America Institute of Nutrition-76 diet.152 However, the effect of arsenic on stone formation remains unclear and no studies of how arsenic content of a stone correlates with its physical properties and whether changes in arsenic homeostasis could affect stone risk have been published.

**Cadmium**

Cadmium is a metal that is considered nonessential and toxic.153 Cadmium is associated with several renal
changes that favour stone formation, including hypercalciumia, hyperphosphaturia, elevated urinary uric acid levels, reduced urinary citrate levels and renal tubular acidosis.\textsuperscript{164} Epidemiological studies indicate that elevated cadmium exposure is associated with a higher incidence of urinary stones.\textsuperscript{155–157} In addition, multiple studies have shown a higher prevalence of urinary stones among individuals with elevated urinary cadmium levels.\textsuperscript{158–160} By contrast, another study with a 12-year follow-up period did not find a strong association between dietary cadmium intake and urinary stone risk at the exposure levels seen in the general population.\textsuperscript{161}

Cadmium might also affect the physical properties of stones: for example, researchers of one study proposed that cadmium might inhibit calcium oxalate crystallization based on known cadmium toxicity mechanisms.\textsuperscript{128} However, the effects of cadmium on lithogenesis are still not clear. When levels are elevated, cadmium can interfere with calcium deposition in bone and make bones brittle.\textsuperscript{162,163} One study found higher levels of cadmium in the nucleus than in the outer crust of calcium-based stones, suggesting that cadmium has a role in the early formation of calcium-based stones.\textsuperscript{164} To our knowledge, no studies have been published that evaluate cadmium content and stone physical properties.

**Tin**

Tin is a metal that is not considered essential, as no metabolic role has been described specifically for it.\textsuperscript{165} Tin has been measured in urinary stones and correlations of its content with other metals and stone chemistry have been studied.\textsuperscript{166} However, the effect of tin on stone formation and stone physical properties and its potential lithogenic risk remain unclear.

**Lanthanides**

The lanthanide group of elements are a series of 15 metals that are not considered essential, as no metabolic role has been described for them to date.\textsuperscript{166} These metals are increasingly used in modern technologies, hence, exposures to lanthanides are increasing each year.\textsuperscript{167} In addition, lanthanum carbonate has been used as a therapeutic to control elevated phosphate levels during renal failure, owing to the highly selective binding of lanthanum to free phosphate.\textsuperscript{168–170} Hyperphosphataemia is a risk factor for nephrolithiasis (especially in children)\textsuperscript{171} but, to date, no reports determining the effect of lanthanum levels on stone formation have been published. In addition, no studies have been reported that evaluate the other lanthanide elements and their effects on lithogenic risk or stone physical properties.

**Elements lacking study on lithogenic effect**

For several elements whose content ranges in calcium-based stones have been analysed and reported (Table 1, Figure 1) no studies have been published that evaluate their effects on lithogenic risk. These elements are titanium, antimony, iodine, barium, germanium and mercury. In addition, no studies have been published that investigated whether their presence in a urinary stone alters the stone’s physical properties. Some of these elements, such as barium, have similar biophysical characteristics to calcium; hence, it is not surprising that they can accumulate in bone.\textsuperscript{110,172}

**The elementome and urinary levels**

Although the elemental content of urinary stones is certainly related to the concentration of elements in the surrounding urine, several investigators have reported
that this relationship is complex and might be strongly affected by other factors in the stone formation processes. Hence, we analysed the relationship between the reported concentrations of elements within calcium-based stones and normal urinary values of these elements provided by clinical reference guides (Figure 2, Table 2). Importantly, our analysis was limited by the characterization of the stone mineral types provided in the previously published reports. Many of these studies aggregated the different types of calcium-based stones into a single category, which could contribute to larger variances in elemental content. Moreover, modern analytical techniques have shown that urinary stones often have a mix of mineral types within the same stones, which would further increase elemental content differences. Despite these limitations, a positive correlation between urinary and stone elemental content exists, with elements that are more abundant in urine also having higher concentrations in urinary stones; however, some elements do show the ability to accumulate in stones, with concentrations in the calculi exceeding urinary levels (for example, aluminium, vanadium and zinc). In addition, many elements (for example, chromium, manganese and molybdenum) have very large ranges of elemental content in stones. Studies designed to determine the reasons for the accumulation or variability of these specific elements could provide important insights into the role of these elements in stone formation. The resulting data could be a starting point for new strategies in the treatment of stone disease, for example through dietary manipulation or pharmacological intervention. Further studies are needed to determine if measuring the levels of specific elements in the urine of individuals at risk of urolithiasis could be a useful way to monitor the development of urinary stone disease.

Conclusions

The previous studies that have analysed the elemental content of stone samples are an important first step in understanding the elemental profiles of human urinary stones. The next step is to begin high-throughput analysis with sensitive elemental detection strategies, focused on chemically defined stone types and involving high numbers of stones, so that the full range and biological variance of the elementome within these calculi can be defined. The resulting data will enable us to connect analytical descriptions of stone composition to criteria that drive clinical impact, and to ultimately answer questions about the aetiology of stone formation in the patient population. For example, for the USA, it is estimated that more than half of the population regularly consumes a diet that is inadequate in magnesium, but whether deficiency in magnesium or any other specific metal micronutrient promotes stone disease is currently unknown.

Similarly, whether excessive supplementation of specific metal micronutrients could also promote lithogenesis is unclear but requires study, as, for example, an estimated 15% of men in the USA use zinc supplements at a level that is higher than the established upper limit of safety. In addition, exposure to specific metal toxins such as cadmium might increase the risk of developing stone disease. Additional studies are needed to clarify the chemical mechanisms underlying stone formation and to elucidate whether some specific elements are key in providing the nidus for crystallisation.

Classifying calcium-based stones into subdivisions according to the amounts of specific elements they contain might be useful to better define therapy for a specific individual. Furthermore, the use of targeted micronutrient supplementation or specific metal chelators might be discovered as new therapeutic possibilities in treating stone disease. Further studies are needed to define whether measurement of levels of specific stone constituents (or levels of specific elements in the urine) can be used to predict stone recurrence once treatment has been successful. Hence, resolving the complete elemental profile of human urinary stones and of stones on a patient-specific basis might be the next key step in improving treatment of urolithiasis.